Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

About Intercept Pharmaceuticals

Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is developing OCA for the treatment of liver diseases, such as primary biliary cirrhosis (PBC), non-alcoholic steatoheptitis (NASH), primary sclerosing cholangitis (PCS) and biliary atresia. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ICPT
  • CUSIP: 45845P10
Key Metrics:
  • Previous Close: $154.96
  • 50 Day Moving Average: $159.42
  • 200 Day Moving Average: $142.47
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.91
  • P/E Growth: -1.36
  • Market Cap: $3.83B
  • Outstanding Shares: 24,726,000
  • Beta: -2.36
Additional Links:
Companies Related to Intercept Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) (?)
Ratings Breakdown: 4 Sell Ratings, 4 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $186.05 (20.06% upside)

Analysts' Ratings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateFirmActionRatingPrice TargetDetails
8/22/2016WedbushReiterated RatingOutperform$239.00View Rating Details
8/18/2016JMP SecuritiesReiterated RatingBuyView Rating Details
8/18/2016FBR & CoReiterated RatingMarket Perform$200.00View Rating Details
8/8/2016Cantor FitzgeraldReiterated RatingSell$60.00View Rating Details
8/5/2016Morgan StanleyReiterated RatingSell$80.00View Rating Details
8/5/2016BMO Capital MarketsReiterated RatingOutperform$219.00 -> $218.00View Rating Details
8/5/2016Oppenheimer Holdings Inc.Lower Price TargetOutperform$265.00 -> $250.00View Rating Details
8/5/2016Credit Suisse Group AGReiterated RatingBuy$200.00View Rating Details
8/5/2016LaidlawDowngradeBuy -> Sell$345.00 -> $105.00View Rating Details
6/15/2016Robert W. BairdReiterated RatingOutperform$332.00View Rating Details
6/1/2016Needham & Company LLCReiterated RatingBuy$350.00View Rating Details
5/31/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
5/31/2016Leerink SwannReiterated RatingHold$144.00 -> $140.00View Rating Details
6/1/2016Barclays PLCReiterated RatingBuy$200.00 -> $205.00View Rating Details
5/31/2016Cowen and CompanyBoost Price TargetOutperform$212.00 -> $215.00View Rating Details
5/31/2016Goldman Sachs Group Inc.Boost Price TargetNeutral$114.00 -> $128.00View Rating Details
4/9/2016Bank of America Corp.Reiterated RatingSell$144.00View Rating Details
1/28/2016S&P Equity ResearchReiterated RatingAverage$100.60 -> $111.91View Rating Details
8/7/2015Janney Montgomery ScottReiterated RatingBuyView Rating Details
7/24/2015Royal Bank Of CanadaReiterated RatingOutperform$490.00View Rating Details
7/1/2015MLV & Co.Reiterated RatingHoldView Rating Details
3/27/2015Deutsche Bank AGBoost Price TargetBuy$300.00 -> $400.00View Rating Details
3/20/2015NomuraSet Price TargetBuy$440.00View Rating Details
12/18/2014Sterne Agee CRTInitiated CoverageBuyView Rating Details
11/4/2014Summer StreetReiterated RatingPositiveView Rating Details
(Data available from 8/28/2014 forward)


Earnings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($3.69)($3.14)$1.72 million$5.52 millionViewN/AView Earnings Details
5/5/2016Q1($3.60)($5.17)$0.64 millionViewN/AView Earnings Details
2/23/2016Q415($3.15)($3.62)$0.43 million$0.45 millionViewListenView Earnings Details
11/9/2015Q315($2.74)($2.10)$0.42 million$0.45 millionViewN/AView Earnings Details
8/5/2015Q215($1.95)($1.99)$2.17 million$0.45 millionViewN/AView Earnings Details
5/11/2015Q115($1.75)($1.78)$1.70 million$1.70 millionViewListenView Earnings Details
3/2/2015Q414($1.53)($1.63)$0.42 million$0.04 millionViewN/AView Earnings Details
11/6/2014Q3($1.02)($1.69)$0.46 million$0.45 millionViewN/AView Earnings Details
8/11/2014Q214($0.12)($0.79)$400.00 million$405.40 millionViewN/AView Earnings Details
5/7/2014($0.72)($1.59)ViewN/AView Earnings Details
3/14/2014Q4 13($0.70)($0.64)ViewN/AView Earnings Details
11/14/2013Q313($0.51)($1.65)$0.89 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.51)($0.79)$0.40 million$0.41 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)
Current Year EPS Consensus Estimate: $-15.75 EPS
Next Year EPS Consensus Estimate: $-14.2 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($4.29)($3.65)($3.83)
Q2 20165($4.12)($3.00)($3.65)
Q3 20164($4.72)($2.80)($3.82)
Q4 20164($4.50)($2.68)($3.82)
Q1 20171($4.19)($4.19)($4.19)
Q2 20171($4.04)($4.04)($4.04)
Q3 20171($3.82)($3.82)($3.82)
Q4 20171($3.52)($3.52)($3.52)
(Data provided by Zacks Investment Research)


Dividend History for Intercept Pharmaceuticals (NASDAQ:ICPT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/25/2016Lisa BrightInsiderSell246$159.00$39,114.00View SEC Filing  
8/1/2016Rachel McminnInsiderSell125$176.57$22,071.25View SEC Filing  
7/5/2016Barbara Gayle DuncanCAOSell146$145.11$21,186.06View SEC Filing  
7/5/2016David ShapiroCMOSell163$145.11$23,652.93View SEC Filing  
7/5/2016Lisa BrightInsiderSell155$145.11$22,492.05View SEC Filing  
7/5/2016Mark PruzanskiCEOSell714$145.11$103,608.54View SEC Filing  
5/25/2016Lisa BrightInsiderSell251$137.50$34,512.50View SEC Filing  
5/2/2016Rachel McminnInsiderSell130$147.49$19,173.70View SEC Filing  
4/4/2016Barbara Gayle DuncanCFOSell144$130.76$18,829.44View SEC Filing  
4/4/2016David ShapiroCMOSell165$130.76$21,575.40View SEC Filing  
4/4/2016Lisa BrightInsiderSell153$130.76$20,006.28View SEC Filing  
4/4/2016Mark PruzanskiCEOSell708$130.76$92,578.08View SEC Filing  
2/25/2016Lisa BrightInsiderSell241$115.22$27,768.02View SEC Filing  
2/1/2016Rachel McminnInsiderSell128$103.56$13,255.68View SEC Filing  
1/13/2016Lisa BrightinsiderSell728$125.52$91,378.56View SEC Filing  
1/4/2016Barbara Gayle DuncanCFOSell468$145.90$68,281.20View SEC Filing  
1/4/2016David ShapiroCMOSell533$145.90$77,764.70View SEC Filing  
1/4/2016Mark PruzanskiCEOSell2,126$145.90$310,183.40View SEC Filing  
1/4/2016Rachel McminnInsiderSell469$145.90$68,427.10View SEC Filing  
11/25/2015Lisa BrightInsiderSell1,150$182.96$210,404.00View SEC Filing  
11/16/2015David ShapiroCMOSell4,264$178.53$761,251.92View SEC Filing  
11/10/2015David ShapiroCMOSell3,500$204.15$714,525.00View SEC Filing  
11/10/2015Klaus R. Dr VeitingerDirectorSell1,000$198.25$198,250.00View SEC Filing  
11/2/2015Rachel McminnInsiderSell125$160.24$20,030.00View SEC Filing  
10/2/2015Barbara Gayle DuncanCFOSell1,054$163.17$171,981.18View SEC Filing  
10/2/2015David ShapiroCMOSell1,140$160.12$182,536.80View SEC Filing  
9/21/2015Nicole WilliamsDirectorSell973$194.82$189,559.86View SEC Filing  
9/15/2015David ShapiroCMOSell3,500$191.28$669,480.00View SEC Filing  
8/17/2015David ShapiroCMOSell4,272$209.37$894,428.64View SEC Filing  
7/20/2015Nicole WilliamsDirectorSell973$279.01$271,476.73View SEC Filing  
7/10/2015Mark PruzanskiCEOSell12,500$250.00$3,125,000.00View SEC Filing  
7/6/2015Luciano AdoriniInsiderSell4,067$579.93$2,358,575.31View SEC Filing  
7/1/2015Barbara Gayle DuncanCFOSell1,000$242.10$242,100.00View SEC Filing  
7/1/2015David ShapiroCMOSell3,781$238.66$902,373.46View SEC Filing  
6/22/2015Nicole WilliamsDirectorSell974$265.14$258,246.36View SEC Filing  
6/15/2015David ShapiroCMOSell3,500$241.58$845,530.00View SEC Filing  
6/8/2015Luciano AdoriniInsiderSell4,000$248.40$993,600.00View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell391$279.07$109,116.37View SEC Filing  
5/6/2015Luciano AdoriniInsiderSell4,000$259.97$1,039,880.00View SEC Filing  
4/20/2015Nicole WilliamsDirectorSell974$278.50$271,259.00View SEC Filing  
4/6/2015Luciano AdoriniInsiderSell4,000$269.64$1,078,560.00View SEC Filing  
4/2/2015David ShapiroCMOSell3,459$275.25$952,089.75View SEC Filing  
3/26/2015Orbimed Advisors LlcDirectorSell157,200$286.75$45,077,100.00View SEC Filing  
3/25/2015Orbimed Advisors LlcDirectorSell207,800$274.41$57,022,398.00View SEC Filing  
3/24/2015Jonathan SilversteinDirectorSell45,600$272.00$12,403,200.00View SEC Filing  
3/23/2015Jonathan SilversteinDirectorSell159,400$275.18$43,863,692.00View SEC Filing  
3/16/2015David ShapiroCMOSell3,500$286.90$1,004,150.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell233$150.01$34,952.33View SEC Filing  
1/5/2015Barbara Gayle DuncanCFOSell141$176.49$24,885.09View SEC Filing  
1/5/2015Daniel Paul ReganInsiderSell146$176.49$25,767.54View SEC Filing  
1/5/2015David ShapiroCMOSell664$172.63$114,626.32View SEC Filing  
1/5/2015Mark PruzanskiCEOSell461$176.49$81,361.89View SEC Filing  
1/2/2015Barbara Gayle DuncanCFOSell1,000$156.40$156,400.00View SEC Filing  
11/17/2014David ShapiroCMOSell4,790$158.82$760,747.80View SEC Filing  
11/12/2014Srinivas AkkarajuDirectorBuy2,000$167.19$334,380.00View SEC Filing  
11/10/2014Klaus R Dr VeitingerDirectorSell233$175.95$40,996.35View SEC Filing  
11/3/2014Mark PruzanskiCEOSell10,000$259.41$2,594,100.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell391$223.65$87,447.15View SEC Filing  
10/2/2014David ShapiroCMOSell5,020$231.63$1,162,782.60View SEC Filing  
10/1/2014Barbara Gayle DuncanCFOSell1,000$233.12$233,120.00View SEC Filing  
10/1/2014David ShapiroCMOSell4,188$231.17$968,139.96View SEC Filing  
10/1/2014Mark PruzanskiCEOSell10,000$228.82$2,288,200.00View SEC Filing  
9/15/2014David ShapiroCMOSell4,000$281.19$1,124,760.00View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell391$280.50$109,675.50View SEC Filing  
9/2/2014Mark PruzanskiCEOSell10,000$286.49$2,864,900.00View SEC Filing  
8/27/2014David ShapiroCMOSell10,000$293.93$2,939,300.00View SEC Filing  
8/26/2014Orbimed Advisors LlcDirectorSell111,258$298.06$33,161,559.48View SEC Filing  
8/25/2014Jonathan SilversteinDirectorSell50,000$295.59$14,779,500.00View SEC Filing  
8/15/2014David ShapiroCMOSell4,774$291.49$1,391,573.26View SEC Filing  
8/12/2014Daniel Paul ReganInsiderSell8,124$325.70$2,645,986.80View SEC Filing  
8/12/2014Klaus R Dr VeitingerDirectorSell316$345.62$109,215.92View SEC Filing  
8/1/2014Mark PruzanskiCEOSell10,000$226.72$2,267,200.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell391$219.15$85,687.65View SEC Filing  
7/7/2014Lorenzo TallarigoDirectorSell2,000$243.06$486,120.00View SEC Filing  
7/2/2014David ShapiroCMOSell5,036$244.73$1,232,460.28View SEC Filing  
7/1/2014Mark PruzanskiCEOSell10,000$250.61$2,506,100.00View SEC Filing  
6/16/2014David ShapiroCMOSell4,000$278.15$1,112,600.00View SEC Filing  
6/2/2014Mark PruzanskiCEOSell10,000$230.60$2,306,000.00View SEC Filing  
5/9/2014Lorenzo TallarigoDirectorSell2,007$254.68$511,142.76View SEC Filing  
5/1/2014Mark PruzanskiCEOSell10,000$263.17$2,631,700.00View SEC Filing  
4/16/2014Mark PruzanskiCEOSell10,000$242.22$2,422,200.00View SEC Filing  
4/14/2014Barbara Gayle DuncanCFOSell1,154$279.00$321,966.00View SEC Filing  
4/10/2014Lorenzo TallarigoDirectorSell349,318$317.71$110,981,821.78View SEC Filing  
4/9/2014Orbimed Advisors LlcDirectorSell81,305$320.00$26,017,600.00View SEC Filing  
4/7/2014Luciano AdoriniInsiderSell2,000$283.90$567,800.00View SEC Filing  
4/2/2014David ShapiroCMOSell5,393$331.83$1,789,559.19View SEC Filing  
3/17/2014David ShapiroCMOSell4,456$437.49$1,949,455.44View SEC Filing  
2/14/2014Paolo FundaroDirectorSell7,246$375.26$2,719,133.96View SEC Filing  
1/16/2014Mark PruzanskiCEOSell10,000$273.68$2,736,800.00View SEC Filing  
1/16/2014Srinivas AkkarajuDirectorSell3,250$267.94$870,805.00View SEC Filing  
1/8/2014David ShapiroCMOSell4,928$71.85$354,076.80View SEC Filing  
1/7/2014Lorenzo TallarigoDirectorSell1,839$67.41$123,966.99View SEC Filing  
1/7/2014Luciano AdoriniInsiderSell1,634$67.41$110,147.94View SEC Filing  
12/16/2013David ShapiroCMOSell5,016$62.11$311,543.76View SEC Filing  
10/21/2013Francesco MicheliMajor ShareholderSell124,912$62.50$7,807,000.00View SEC Filing  
10/21/2013Jonathan SilversteinDirectorSell40,088$62.50$2,505,500.00View SEC Filing  
10/21/2013Luciano AdoriniInsiderSell2,000$55.51$111,020.00View SEC Filing  
10/15/2013Francesco MicheliMajor ShareholderSell1,123,415$62.50$70,213,437.50View SEC Filing  
10/15/2013Orbimed Advisors LlcDirectorSell376,585$62.50$23,536,562.50View SEC Filing  
10/2/2013David ShapiroCMOSell4,392$72.80$319,737.60View SEC Filing  
9/20/2013Luciano AdoriniInsiderSell2,000$61.07$122,140.00View SEC Filing  
9/17/2013Mark PruzanskiCEOSell25,000$52.00$1,300,000.00View SEC Filing  
9/13/2013Mark PruzanskiCEOSell12,500$49.02$612,750.00View SEC Filing  
8/20/2013Luciano AdoriniInsiderSell2,000$44.18$88,360.00View SEC Filing  
8/16/2013David ShapiroCMOSell5,016$49.20$246,787.20View SEC Filing  
8/15/2013David ShapiroCMOSell4,754$45.04$214,120.16View SEC Filing  
8/12/2013Mark PruzanskiCEOSell12,500$45.98$574,750.00View SEC Filing  
8/12/2013Paolo FundaroDirectorSell4,759$46.13$219,532.67View SEC Filing  
7/22/2013Luciano AdoriniInsiderSell2,000$49.44$98,880.00View SEC Filing  
7/15/2013Mark PruzanskiCEOSell25,000$50.05$1,251,250.00View SEC Filing  
7/9/2013Mark PruzanskiCEOSell37,500$46.36$1,738,500.00View SEC Filing  
7/8/2013Barbara Gayle DuncanCFOSell25,000$45.39$1,134,750.00View SEC Filing  
7/2/2013David ShapiroCMOSell4,369$43.63$190,619.47View SEC Filing  
6/26/2013Mark PruzanskiCEOSell12,500$40.06$500,750.00View SEC Filing  
6/20/2013Luciano AdoriniInsiderSell2,000$37.07$74,140.00View SEC Filing  
6/20/2013Mark PruzanskiCEOSell25,000$38.25$956,250.00View SEC Filing  
6/19/2013Barbara Gayle DuncanCFOSell50,575$34.50$1,744,837.50View SEC Filing  
6/17/2013David ShapiroCMOSell5,016$32.72$164,123.52View SEC Filing  
5/28/2013Barbara Gayle DuncanCFOSell6,225$34.50$214,762.50View SEC Filing  
5/20/2013Barbara Gayle DuncanCFOSell28,200$34.50$972,900.00View SEC Filing  
5/16/2013David ShapiroCMOSell5,016$31.31$157,050.96View SEC Filing  
4/9/2013David ShapiroCMOSell3,750$34.41$129,037.50View SEC Filing  
10/16/2012Jonathan SilversteinDirectorBuy333,334$15.00$5,000,010.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateHeadline logoIntercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : August 26, 2016 (NASDAQ:ICPT) - August 26 at 8:33 AM
News IconIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Consensus Take & Valuation - Post News (NASDAQ:ICPT) - August 23 at 5:44 PM logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Gets 1 Recommendations To Sell - Investor Newswire (NASDAQ:ICPT) - August 23 at 5:44 PM logoIntercept Pharmaceuticals (ICPT) Shares Have Over 18% Upside: FBR Capital - TCC (NASDAQ:ICPT) - August 19 at 5:32 PM logoINTERCEPT PHARMACEUTICALS INC (NASDAQ:ICPT) - August 18 at 5:35 PM logoINTERCEPT PHARMACEUTICALS : New England Journal of Medicine Publishes Results .. (NASDAQ:ICPT) - August 18 at 5:35 PM logoINTERCEPT PHARMACEUTICALS INC Financials (NASDAQ:ICPT) - August 18 at 5:35 PM logoINTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:ICPT) - August 18 at 5:35 PM logoIntercept Pharma (ICPT) Announces NEJM Published Results of ... - (NASDAQ:ICPT) - August 18 at 8:36 AM logoIntercept Pharma (ICPT) Announces NEJM Published Results of Phase 3 POISE Trial of Ocaliva for PBC (NASDAQ:ICPT) - August 17 at 5:47 PM logoNew England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva® (Obeticholic Acid) for the Treatment of PBC (NASDAQ:ICPT) - August 17 at 5:47 PM logoWill Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Hit $332 Price Target? - Investor Newswire (NASDAQ:ICPT) - August 17 at 8:37 AM logoNeedham Remains Sidelined on Arena Pharmaceuticals, Inc. (ARNA) Following Quarterly Corporate Update (NASDAQ:ICPT) - August 11 at 5:49 PM logoCan Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Surprise ... - Investor Newswire (NASDAQ:ICPT) - August 10 at 8:24 AM logoINTERCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:ICPT) - August 10 at 8:24 AM logoETF’s with exposure to Intercept Pharmaceuticals, Inc. : August 9, 2016 (NASDAQ:ICPT) - August 9 at 5:43 PM logoIntercept Pharmaceuticals, Inc. :ICPT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 (NASDAQ:ICPT) - August 8 at 5:45 PM logoIntercept (ICPT) Reports Narrower-than-Expected Q2 Loss (NASDAQ:ICPT) - August 8 at 10:17 AM logoIntercept Pharma downgraded by Laidlaw (NASDAQ:ICPT) - August 5 at 5:42 PM logoAnalysts Observing Stocks Update: Hill-Rom Holdings Inc (NYSE ... - Street Updates (NASDAQ:ICPT) - August 5 at 8:32 AM logoIntercept Pharmaceuticals, Inc. (ICPT) Reported Q2 Revenue of More Than Thrice The Consensus - TCC (NASDAQ:ICPT) - August 5 at 8:32 AM logoIntercept Pharmaceuticals Inc (ICPT) Reported Q2 Revenue of More Than Thrice The Consensus (NASDAQ:ICPT) - August 4 at 5:52 PM logoIntercept (ICPT) Posts Narrower-Than-Expected Loss in Q2 (NASDAQ:ICPT) - August 4 at 5:52 PM logoIntercept Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:ICPT) - August 4 at 8:35 AM logoIntercept reports 2Q loss (NASDAQ:ICPT) - August 4 at 8:35 AM logoINTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:ICPT) - August 4 at 8:35 AM logoIntercept (ICPT) Likely to Beat in Q2 Earnings: Stock to Gain? (NASDAQ:ICPT) - August 2 at 10:23 AM logoZoetis (ZTS): Stock to Beat Earnings Estimates in Q2 Again (NASDAQ:ICPT) - August 1 at 5:28 PM logoCarmignac Gestion Bought A Lot More Intercept Pharmaceuticals ... - Finance Daily (NASDAQ:ICPT) - July 28 at 8:34 AM logoIntercept to Report Second Quarter 2016 Financial Results on August 4 and Present at Upcoming Conference (NASDAQ:ICPT) - July 28 at 7:18 AM logoCan Shares Of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Hit $332? - Investor Newswire (NASDAQ:ICPT) - July 27 at 8:24 AM logoMerck (MRK) Q2 Earnings: Will The Stock Pull A Surprise? (NASDAQ:ICPT) - July 26 at 8:30 AM logoVertex (VRTX) to Report Q2 Earnings: Is a Surprise in Store? (NASDAQ:ICPT) - July 25 at 10:09 AM
News IconIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:ICPT) - July 22 at 5:31 PM
News IconTrading Examination: Performance check on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - TGP (NASDAQ:ICPT) - July 22 at 5:31 PM
News IconInvestor Attention Turning to Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Engelwood Daily (NASDAQ:ICPT) - July 22 at 5:31 PM logoBroker Outlook For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Fiscal Standard (NASDAQ:ICPT) - July 22 at 5:31 PM
News IconAttention Grasping Stock With Upward Momentum: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - TGP (NASDAQ:ICPT) - July 22 at 5:31 PM logoINTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of Matters t (NASDAQ:ICPT) - July 22 at 5:02 PM
News IconIntercept Pharmaceuticals Incorporated (NASDAQ:ICPT) Shorted Shares Increased By 2.43% - Press Telegraph (NASDAQ:ICPT) - July 22 at 8:32 AM
News IconHigh Expectations Remain For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - TGP (NASDAQ:ICPT) - July 22 at 8:32 AM
News IconSession Focus: Performance Watch on Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - TGP (NASDAQ:ICPT) - July 20 at 3:33 PM
News IconInvestor Gauge: Price Target and Earnings Review for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - TGP (NASDAQ:ICPT) - July 20 at 3:33 PM
News IconEPS Growth in Focus for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - TGP (NASDAQ:ICPT) - July 20 at 3:33 PM
News IconEquity Roundup: Stock Performance Focus on Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Press Telegraph (NASDAQ:ICPT) - July 20 at 8:34 AM
News IconShares Positive Over the Past Month: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - TGP (NASDAQ:ICPT) - July 20 at 8:34 AM
News IconIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Stock Insight and Session Performance Spotcheck - Press Telegraph (NASDAQ:ICPT) - July 19 at 5:40 PM
News IconAnalysts Bullish on Stock: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - TGP (NASDAQ:ICPT) - July 19 at 5:40 PM
News IconSession Focus - Highlighting Shares of: Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - TGP (NASDAQ:ICPT) - July 19 at 5:40 PM
News IconConsensus Analyst Target Price Check for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) - Press Telegraph (NASDAQ:ICPT) - July 19 at 5:40 PM


Intercept Pharmaceuticals (NASDAQ:ICPT) Chart for Sunday, August, 28, 2016

Last Updated on 8/28/2016 by Staff